AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 282 min read$CNMD

Conmed (CNMD) Q3 Earnings Top Estimates

Conmed (CNMD) reported Q3 earnings of $1.04 per share, beating estimates by $0.04. Revenue was $335.56M, missing estimates by 0.37%. The company has beaten EPS estimates four times in the last four quarters. Shares are up 16.3% YTD. The Zacks Rank for the stock is #3 (Hold).

Original reporting
finance.yahoo.com
Published Oct 28, 2026, 10:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 6:24 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$CNMD
Bullish
high confidence
Mentioned
$CNMD
Relevance
8/10
AlphAI data visualization · based on finance.yahoo.com
Decision brief

The 30-second read

$CNMDBullishMed
01

Why it matters

The earnings surprise could prompt short‑term buying, but the revenue miss and unchanged Zacks Rank temper long‑term expectations.

02

Market read

Earnings beat provides a short‑term trade idea; broader market impact is minimal.

03

What to watch

Guidance for the next quarter is flat, and the Zacks Rank remains a Hold, indicating limited upside momentum.

Relevance 8/10Novelty 8/10Timing: post‑earnings today

Background

Conmed (CNMD) is a medical technology company in the Zacks Medical‑Dental Supplies industry.

Company-level read

Ticker impact

$CNMDBullishHigh confidence
Context

Conmed reported Q3 EPS of $1.04, beating the $1 consensus estimate, and posted a 4% earnings surprise.

Expected impact

likely modest upside as market prices in the EPS beat, though revenue miss tempers enthusiasm

Evidence & confidence

EPS beat is a fresh, material fact; investors typically reward earnings surprises, but the revenue shortfall limits the upside.

Market effects

Sector

Medical technology sector may see slight uplift as Conmed's beat suggests resilience in the market.

Regional

U.S. small‑cap healthcare stocks could see modest buying interest.

Global

Limited; impact confined to U.S. healthcare investors.

Counterpoint

What could challenge this read

Revenue miss and modest EPS beat may signal underlying demand weakness, suggesting caution.

Key entities

  • company
    Conmed

    Medical technology firm reporting Q3 results.

Read at source← All news

StoryCONMED posts Q3 2026 results, beats adjusted EPS and lifts full‑year EPS guidance

Also covered by

5 outlets

Related articles

OCT 29
$CNMDHighAI 8/10

CONMED Q3 Earnings Call Highlights

CONMED reported Q3 organic revenue growth of 7.2% in orthopedic surgery, driven by international demand and BioBrace. Adjusted gross margin increased to 56.4%. The company updated its 2026 outlook, narrowing revenue growth to 5%-5.5% and raising adjusted EPS guidance to $4.54-$4.61. CONMED repurchased 1.2 million shares and expects to allocate $62 million to buybacks for the year.

finance.yahoo.com3 min
OCT 29
$CNMDMed

CONMED (CNMD) Q3 2026 Earnings Call Transcript

CONMED (CNMD) reported Q3 2026 net revenue of $335.6M, with organic growth of 6.7% YoY. Adjusted EPS was $1.04, exceeding expectations. AirSeal and Buffalo Filter drove sales growth, with AirSeal showing strong performance in robotic and laparoscopic surgery. The company remains optimistic about long-term growth prospects for these products.

finance.yahoo.com3 min
OCT 28
$CNMDHighAI 8/10

CONMED (NYSE:CNMD) posts Q3 2026 sales in line with estimates

CONMED (CNMD) reported Q3 2026 revenue of $335.6M, flat year-on-year but in line with estimates. Adjusted EPS of $1.04 beat estimates by 3.7%. The company reconfirmed its full-year revenue guidance of $1.36B and slightly raised its EPS guidance to $4.58. Operating margin decreased to 11.1% from 3.5% year-on-year. Long-term revenue growth has slowed, with a 6.7% CAGR over five years.

finance.yahoo.com2 min
OCT 28
$CNMDHighAI 8/10

Conmed: Q3 Earnings Snapshot

Conmed Corp. (CNMD) reported Q3 profit of $19.8M, or 66c/share, beating estimates. Revenue was $335.6M. Full-year EPS guidance is $4.54-$4.61, with revenue of $1.36B-$1.37B. According to Zacks, analysts expected $1.04 per share.

finance.yahoo.com1 min